These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 3798406)
21. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Chong BH; Pitney WR; Castaldi PA Lancet; 1982 Dec; 2(8310):1246-9. PubMed ID: 6128550 [TBL] [Abstract][Full Text] [Related]
22. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Bertele V; De Gaetano G Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787 [TBL] [Abstract][Full Text] [Related]
24. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis. Kondo K; Seo R; Naka M; Kitagawa T; Wakitani K; Sakata M; Kira H; Okegawa T; Kawasaki A Eur J Pharmacol; 1989 Apr; 163(2-3):253-61. PubMed ID: 2721574 [TBL] [Abstract][Full Text] [Related]
25. 9,11-epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human platelets. Fitzpatrick FA; Bundy GL; Gorman RR; Honohan T Nature; 1978 Oct; 275(5682):764-6. PubMed ID: 703845 [No Abstract] [Full Text] [Related]
26. Platelet function and biosynthesis of prostacyclin and thromboxane A2 in whole blood after aspirin administration in human subjects. Mehta JL; Mehta P; Lopez L; Ostrowski N; Aguila E J Am Coll Cardiol; 1984 Oct; 4(4):806-11. PubMed ID: 6384329 [TBL] [Abstract][Full Text] [Related]
27. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979 [TBL] [Abstract][Full Text] [Related]
28. [Problems of a pharmacologic search for inhibitors of platelet aggregation]. Lakin KM Kardiologiia; 1988 Oct; 28(10):120-6. PubMed ID: 3066962 [No Abstract] [Full Text] [Related]
29. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid. Seuter F; Perzborn E; Rosentreter U; Böshagen H; Fiedler VB Arzneimittelforschung; 1989 Dec; 39(12):1525-7. PubMed ID: 2624599 [TBL] [Abstract][Full Text] [Related]
31. Thrombin is an important mediator of cyclic coronary blood flow variations due to platelet aggregation in stenosed canine coronary arteries. Eidt JF; Allison P; Noble S; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT Trans Assoc Am Physicians; 1988; 101():125-36. PubMed ID: 3269674 [No Abstract] [Full Text] [Related]
32. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. Mikhailidis DP; Barradas MA; Maris A; Jeremy JY; Dandona P J Clin Pathol; 1985 Oct; 38(10):1166-71. PubMed ID: 3902901 [TBL] [Abstract][Full Text] [Related]
33. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Le Breton GC; Venton DL; Enke SE; Halushka PV Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066 [TBL] [Abstract][Full Text] [Related]
34. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Patscheke H; Stegmeier K Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261 [TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs. Higo K; Karasawa A Jpn J Pharmacol; 1993 Dec; 63(4):521-3. PubMed ID: 8121085 [TBL] [Abstract][Full Text] [Related]
36. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation. Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196 [TBL] [Abstract][Full Text] [Related]
37. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate. Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011 [TBL] [Abstract][Full Text] [Related]